Clinical Trial Update: Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the safety and efficacy of HSK39004 in Chinese patients with chronic obstructive pulmonary disease, using two formulations (dr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• HSK39004 Dry Powder Inhaler (HSK39004)
• HSK39004 Inhalation Suspension (HSK39004)

Snippet

Sponsor: Haisco Pharmaceutical Group Co., Ltd. | Conditions: Chronic Obstructive Lung Disease (COLD) | Phase 2 | Status: ACTIVE_NOT_RECRUITING